Glimepiride Eg

Glimepiride Eg is a generic oral tablet containing the active ingredient glimepiride. It belongs to the sulfonylurea class of antidiabetic agents and is marketed in the European Union. The medication is prescribed for the management of blood glucose levels in adults with type 2 diabetes mellitus. It is available only with a prescription and is taken by mouth once daily as directed by a healthcare professional.

Glimepiride Eg is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and weight management alone are insufficient to achieve target glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be used as monotherapy or in combination with other oral antidiabetic agents. - May be considered when patients require a sulfonylurea with a long duration of action. - Helps reduce HbA1c when taken consistently as prescribed. - Intended for adult patients with adequate pancreatic beta‑cell function.

Glimepiride Eg may cause a range of adverse effects, some of which are frequent and mild, while others are less common but potentially serious.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as rash, itching, or swelling of the face and throat. - Blood disorders including leukopenia or thrombocytopenia.

Before starting Glimepiride Eg, certain health conditions and patient factors should be evaluated to minimize risks.

- Assess renal and hepatic function; dose adjustments may be needed in impairment. - Use cautiously in elderly patients due to increased hypoglycemia risk. - Not recommended during pregnancy or breastfeeding because safety data are limited. - Monitor blood glucose regularly to detect hypoglycemia early. - Avoid alcohol consumption, which can potentiate hypoglycemic episodes. - Review concomitant medications that affect insulin secretion or glucose metabolism. - Ensure patients have adequate pancreatic beta‑cell reserve before initiating therapy.

Glimepiride Eg can interact with several drugs, altering its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride plasma levels. - MAO‑B inhibitors (e.g., selegiline) that can enhance hypoglycemic risk.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can increase blood glucose levels. - Corticosteroids or atypical antipsychotics, which may reduce glimepiride effectiveness.